Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Politics / Policy/  Cipla-Novartis patent row: DIPP looking into merit of case
BackBack

Cipla-Novartis patent row: DIPP looking into merit of case

DIPP is examining whether the issues of 'public interest' or 'mischievous to the State', as prescribed under the Indian Patent Act, is applicable

As per the Indian Patent Act, the department is bound to give an opportunity to Novartis, to be heard before taking any decision on the matter. Photo: S.Kumar/MintPremium
As per the Indian Patent Act, the department is bound to give an opportunity to Novartis, to be heard before taking any decision on the matter. Photo: S.Kumar/Mint

New Delhi: The commerce and industry ministry is looking into the merit of Cipla Global Ltd’s demand for revocation of patents of Swiss drug major Novartis AG for respiratory drug Indacaterol citing the need for public health access.

The Department of Industrial Policy and Promotion (DIPP) has started the exercise on Cipla’s demand. It is examining whether the issues of “public interest" or “mischievous to the State" as prescribed in the Section 66 of the Indian Patent Act (IPA) 1970 is applicable, according to sources.

“The department has received the Cipla’s case and it is looking into the merit of the case," a source said. Under Section 66 of IPA, the Centre can revoke a patent in “public interest" if it is of the opinion that a patent or the mode in which it is exercised is “mischievous to the State" or generally prejudicial to the public.

However, as per the Act, the department is bound to give an opportunity to Novartis to be heard before taking any decision on the matter.

Since the procedure undertaken by the DIPP is quasi-judicial in nature, the case could take substantial time to reach a final decision.

Cipla has asked the DIPP to revoke five patents of Novartis relating to the product citing need for public health access and stated the patent holder Novartis does not manufacture the drug in India.

Last week, the Indian firm launched its low-cost generic version of the Swiss drug maker’s respiratory drug Indacaterol sold under the Onbrez brand.

Elaborating the reasons for approaching the DIPP to revoke the patents, Cipla had said: “Novartis has been granted these patents since 2008-09 but has chosen not to manufacture the same in India." Novartis merely imports a negligible quantity of these products manufactured in Switzerland as per its own data filed before the Patent office, Cipla had said.

The import for 2013 as declared by Novartis in the Patent office is a meagre 53,844 units which do not satisfy even 4,500 patients annually.

The shortage is more than 99.97%, it added. Cipla claimed there are more than 1.5 crore patients in India who need the drug.

These are the declared numbers of patients and it could be even more considering the high prevalence of the chronic obstructive pulmonary disease in urban and rural areas.

Last year in April, Novartis had lost a seven-year long legal battle for getting its blood cancer drug Glivec patented in India and to restrain Indian companies from manufacturing generic drugs, with the Supreme Court rejecting the multinational company’s plea.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Politics News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 02 Nov 2014, 12:12 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App